First-Line Icotinib In Elderly Patients With Non-Small Cell Lung Cancer Harboring Active Egfr Mutation: A Multi-Center, Single-Arm Study.

e20519Background: Increasing elderly patients suffer from non-small cell lung cancer (NSCLC) due to aged population, which is associated with more comorbidities and reduced organ function. Here we present a phase 2, single-arm study to evaluate first-line icotinib in elderly NSCLC patients harboring EGFR mutation. Methods: Chemotherapy-naive patients aged 70 years or older with stage IIIB or IV NSCLC with activating EGFR mutation (exon 19 deletion and L858R mutation in exon 21) were enrolled and treated with oral icotinib (125 mg, three times per day) until disease progression. The primary endpoint was progression-free survival (PFS). This study was registered at ClinicalTrials.gov as NCT01646450. Results: Between October 12, 2012 and February 12, 2014, 35 patients were enrolled and received treatment per protocol at 3 sites in China. The median age was 76.4 years, most patients had stage IV disease (71.4%) with ECOG performance status 0-1 (85.7%). Hypertension was the most common comorbidity (56%), follo...